2015
DOI: 10.11604/pamj.2015.22.273.2311
|View full text |Cite
|
Sign up to set email alerts
|

Non invasive assessment of liver fibrosis in chronic hemodialysis patients with viral hepatitis C

Abstract: The liver biopsy has long been the "gold standard" for assessing liver fibrosis in patients with hepatitis C. It's an invasive procedure which is associated with an elevated bleeding, especially in chronic hemodialysis patients. Main goal is to assess liver fibrosis in chronic hemodialysis with HCV by Fibroscan and by biological scores (APRI, Forns and Fib-4), and to measure the correlation between these tests. Cross-sectional study including all chronic hemodialysis patients with hepatitis C virus, in two pub… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0
6

Year Published

2019
2019
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(11 citation statements)
references
References 15 publications
0
5
0
6
Order By: Relevance
“…Due to potential complications, no patient underwent liver biopsy for evaluation. In patients undergoing hemodialysis, non-invasive fibrosis tests represent a satisfactory alternative in the assessment of hepatic fibrosis [11]. Viral infection was evaluated by quantitative HCV ribonucleic acid (RNA) determination, at the beginning of therapy, at the end of treatment (EOT) and at 12 weeks after EOT, using the Roche COBAS® Ampliprep TNAI/TaqMan® 48 RUO Assay for HCV RNA Quantification for HCV in human serum or EDTA plasma samples.…”
Section: Methodsmentioning
confidence: 99%
“…Due to potential complications, no patient underwent liver biopsy for evaluation. In patients undergoing hemodialysis, non-invasive fibrosis tests represent a satisfactory alternative in the assessment of hepatic fibrosis [11]. Viral infection was evaluated by quantitative HCV ribonucleic acid (RNA) determination, at the beginning of therapy, at the end of treatment (EOT) and at 12 weeks after EOT, using the Roche COBAS® Ampliprep TNAI/TaqMan® 48 RUO Assay for HCV RNA Quantification for HCV in human serum or EDTA plasma samples.…”
Section: Methodsmentioning
confidence: 99%
“…As an index of hepatic fibrosis, various validation studies have been done on FIB4 [8,9,13,14,15,18,19,20,21,22,23,24,25]. Usefulness of the index was demonstrated not only in patients with HCV but also in patients with non-alcoholic fatty liver disease and alcoholic liver disease.…”
Section: Discussionmentioning
confidence: 99%
“…1,2 Este estadiamento pode ser realizado por qualquer um dos seguintes métodos: biópsia hepática, FibroScan, ARFI, ressonância magnética, APRI, FIB4, APRI modificado, Fibrotest, Fornix Index, dentre outros. 3,4,5 No Brasil, são aceitos os métodos disponíveis no SUS: biópsia hepática, FibroScan, ARFI, APRI e FIB4. 1 A biópsia hepática é considerada o padrão ouro, 6 porém, é um método invasivo que envolve risco de complicações, como sangramento, fístula biliar, perfuração, infecção, dor local e raros óbitos.…”
Section: Introductionunclassified
“…Necessita a obtenção de amostra de tecido hepático com pelo menos 10 espaços porta para um resultado conclusivo 6 e que tem possibilidade de divergência de interpretação de resultados, mesmo entre patologistas experientes. 5 Por essas limitações da biópsia hepática é que se buscam outros métodos de estadiamento da fibrose hepática. O teste ideal deve ter boa acurácia, baixo potencial de complicações, ser replicável, ter baixo custo e ser acessível até mesmo em países subdesenvolvidos.…”
Section: Introductionunclassified
See 1 more Smart Citation